News & Views
Collaboration to Develop Tumour Progression Regulator Leads
Oct 18 2020 Read 167 Times
UK-based biopharmaceutical company Phoremost and AI driven pharmatech XtalPi, have signed an agreement to identify and develop compounds to advance a drug discovery program against targets that epigenetically regulate tumour progression and which have been previously classified as ‘undruggable’. The companies will pursue this challenging goal with a unique combination of machine learning and physics-based computation methods, using XtalPi’s intelligent digital drug discovery and development (ID4) platform, to explore novel sites discovered by PhoreMost’s SITESEEKER® platform.
“XtalPi’s AI-based ID4 and PhoreMost’s SITESEEKER are highly complementary platforms, and we look forward to working together with the team. This alliance marks an exciting chapter in PhoreMost’s development, as we now seek to rapidly progress our internal portfolio of novel first-in-class targets into drug discovery,” said Phoremost CEO Dr Chris Torrance.
“Today, many diseases lack effective treatment because their corresponding targets are too challenging for traditional drug discovery methods.,” added Dr Jian Ma, co-founder and CEO of XtalPi. “We are excited to combine PhoreMost’s target discovery technology with our ability to quickly identify lead compounds with desirable drug properties, and continuously translate high-quality ‘undruggable’ targets into first-in-class pipeline assets to address unmet medical needs.
More information online
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
The following Buyers’ Guide has been produced by International Labmate Ltd. International Labmate have been publishing magazines for over 46 years. We now publish 9 laboratory, environmental and...
View all digital editions
Nov 05 2020 Istanbul, Turkey
Nov 10 2020 Karachi, Pakistan
Nov 11 2020 Chiba City, Japan
Nov 12 2020 Shanghai, China
Nov 15 2020 Virtual event